“Mr. Thira” updates Paxlovid’s “COVID-19” information, reducing hospitalizations by 55%

On February 12, 2023, Assoc. Prof. Thira Worathanarat or “Doctor Thira“Chulalongkorn University Faculty of Medicine Facebook post about the issue”COVID 19” indicates that

yesterdayaround the world he added 85,560 people, 399 more deaths, total 677,384,501 people dieA total of 6,781,153 people

The 5 Most Infected in

  1. Japan
  2. Taiwan
  3. Russia
  4. South Korea
  5. Austria

As of yesterday, in the number of new infections, countries from Europe and Asia occupied nine of the top 10 and 18 of the top 20 globally.

The number of new infections per day worldwide at the moment from Asia and Europe Together, it accounted for 97.76 percent of the world, while the number of deaths accounted for 89.47 percent.

Major update on COVID-19 today.

1. Paxlovid reduces hospitalization by 55% and reduces the risk of death by 85%.

Aggrawal NR and colleagues from the University of Colorado, USA, published the study in The Lancet Infectious Diseases on February 10.

The study was conducted between March and August 2022 to compare the morbidity rate leading to hospital admissions and the 28-day mortality rate among people infected with COVID-19. Of the 21,493 patients with mild symptoms, 9,881 had a history of taking Paxlovid and 11,612 did not.

The study found that taking Paxlovid reduced the risk of hospitalization by 55% and the risk of death by 85%.

2. For how long will the vaccine protect us?

Wu N and colleagues from Canada A systematic review of the research was conducted. and performed a meta-analysis. To find out if the COVID-19 vaccination How long will it be effective in reducing the risk of infection, illness and death?

Published February 10 in The Lancet Respiratory Medicine journal.

A review of past studies up to December 2022 with a total of 68 studies involving four vaccines, namely BNT162b2. [Pfizer–BioNTech]mRNA-1273 [Moderna]ChAdOx1 nCoV-19 [AZD1222; Oxford–AstraZeneca]and Ad26.COV2.S [Janssen]

It can be concluded that completing the first course of vaccination (primary series) reduces the risk of infection by an average of 83% in the first 3 months after vaccination. But it quickly drops to 62% after 4 months.

Although it reduced the risk of serious illness by an average of 92%, it fell to 79% after 8 months and the risk of death reduced by an average of 91%, down to 86% after 6 months.

However, what must be emphasized is the age that has been Omicron cases, it was found that the effectiveness of the vaccine would decrease even more. infections, illnesses and deaths

In addition, if you look at the performance ofbooster vaccination Most of the available studies were during the outbreak of Omicron, with an average of 70% effectiveness in preventing infection, but it dropped to 43% 4 months after the booster.

And reduces the risk of serious illness by 89%, but drops to around 71% 4 months after the injection, research data so far is not enough to draw a conclusion about the effectiveness of the booster vaccine in reducing deaths.

The results of this study highlight the importance of booster vaccination. Especially in the age of Omicron, a long epidemic like today.

and if following other research that has come to be exchanged all the time it is found to be consistent Several studies have shown its effectiveness in reducing the risk of serious illness and death. after a needle injection It should be at a level high enough to protect for about 7-11 months

3. Immune disorders among Long COVID patients

Yin K and colleagues from UCSF, USA Disseminate the results of laboratory studies. By comparing the immunological characteristics of the blood of a group of Long COVID patients with those of a previously infected but non-Long COVID group

Published in bioRxiv February 10.

find a groupLong COVID patients CD4 T cells are characterized by an abnormal T cell immune system, with large numbers of CD4 T cells accumulating in the tissues where inflammation occurs. and functional exhaustion of CD8 T cells.

The research team expects that immune abnormalities in Long COVID patients may result from the presence of the virus in the body. This is consistent with the assumptions of other research teams around the world.


1. Aggrawal NR et al. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 in the lifetime of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. The Lancet Infectious Diseases. 10 February 2023.

2. Wu N et al. Long-term effectiveness of COVID-19 vaccines against infections, hospitalizations, and deaths in adults: findings from a rapid live systematic evidence synthesis and meta-analysis through December 2022. The Lancet Respiratory Medicine. 10 February 2023.

3. Yin K et al. Prolonged COVID manifests with T-cell dysregulation, inflammation, and an uncoordinated adaptive immune response to SARS-CoV-2. bioRxiv. 10 February 2023.


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.